Citi raised the firm’s price target on Ligand (LGND) to $282 from $276 and keeps a Buy rating on the shares after the company’s partner Travere received FDA approval of Filspari for the treatment of focal segmental glomerulosclerosis.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND:
- Ligand price target raised to $243 from $239 at H.C. Wainwright
- This Is Why Travere Therapeutics Stock (TVTX) Surged Today
- Ligand price target raised to $250 from $244 at BofA
- Ligand partner Travere Therapeutics announces FDA approval for Filspari
- Citi ups Ligand target, opens ‘upside 90-day catalyst watch’